Foghorn Q3 net loss narrows to $15.8M; CFO Humer resigns; cash runway into 2028

Foghorn Therapeutics Inc.

2025-Q3 EPS reported -$0.84 revenue$21,662,000

CFO Kristian Humer resigns effective Nov 14, 2025 to pursue other opportunity; no disagreement with company.
Q3 2025 net loss $15.8M vs $19.1M YoY; collaboration revenue $8.2M (vs $7.8M); R&D expenses $20.0M.
Cash, equivalents, and marketable securities $180.3M as of Sept 30, 2025; provides cash runway into 2028.
FHD-909 (SMARCA2 inhibitor) Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; combination data with pembrolizumab and KRAS inhibitors.
Selective CBP degrader IND-ready in 2026; EP300 degrader IND-enabling studies in 2026; ARID1B degrader advancing to in vivo POC in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.